Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: MarkR37 who wrote (4558)	10/4/2000 1:36:34 PM
From: rkrw	Read Replies (1) \| Respond to of 10280

<<What are the chances Nora will be one of the 10?>> Barring the unforeseen, 100%. NDA filing is expected this year.

To: MarkR37 who wrote (4558)	10/4/2000 8:08:29 PM
From: hm	Read Replies (1) \| Respond to of 10280

>>Burn rate in 2000 200-250 million >>Will launch 10 drugs over 4 years using >>own sales force Did SEPR offer burn rates projections beyond 2000? Building a sales force(s) and launching 10 drugs is a very expensive proposition. It's a long way from selling Xopenex to selling their portfolio. As a point of reference, Schering spends around $300 million / year in support of Claritin. SEPR will have to spend big to get adequate share of voice. If SEPR goes for it, might expect them to buy a sales + marketing organization similar to Elan - Dura and Celltech - Medeva. my two cents hm